Do cardiovascular risk factors modify the cardiotoxicity of lymphoma treatments?

Nathanael S Gray

MALT1 inhibitors for the treatment of chemo-resistant ABC-DLBCL

Non-Hodgkin lymphoma

Hematology and hematologic malignancies Pathology

Christopher S Carlson

Monitoring disease progression in follicular lymphoma with next-gen sequencing

Non-Hodgkin lymphoma

Pathology

Investigator from Dana–Farber Cancer Institute

Nursing Oncology Capacity Building through Fellowship Programs in Rwanda and Haiti

Non-Hodgkin lymphoma

Corey Casper

Uganda Cancer Institute / Hutchinson Center Cancer Alliance (UCI/HCCA)

Hodgkin lymphoma Non-Hodgkin lymphoma

Dean W Felsher

Prognostic Metabolic Signatures of Cancers Through Mass Spectrometry Imaging

Hodgkin lymphoma Non-Hodgkin lymphoma

Hematology and hematologic malignancies

Manoj Menon

AMC PROTOCOL #075: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin’s Lymphoma. A Trial of the AIDS Malignancy Consortium (AMC)

Hodgkin lymphoma

Hematology and hematologic malignancies

Theodore S Jardetzky

Inhibitors of the Epstein-Barr Virus Entry Machinery

Hodgkin lymphoma Non-Hodgkin lymphoma

Martha Lassiter

Duke University Nursing Oncology Training Exchange with Tata Memorial Hospital

Non-Hodgkin lymphoma Hodgkin lymphoma

Franziska Michor

Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies

Hodgkin lymphoma Non-Hodgkin lymphoma